mAbxience's MB02 (biosimilar- bevacizumab) Receives EC's Approval for the Treatment of Cancer
Shots:
- The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum- BC- NSCLC- RCC- epithelial ovarian- fallopian tube or primary peritoneal cancer- and carcinoma of the cervix
- Mabxience’s MB02 to be marketed as Alymsys and Oyavas both show comparable quality- safety & efficacy to Avastin (bevacizumab)
- The launch of Bevacizumab has provided high quality- affordable medicine and opportunity to the healthcare system and improve patient access to biological treatments throughout the EU
Ref: PRNewswire | Image: Adobe Stock
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com